Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012

Schroten-Loef, Caroline; Verhoeven, Rob H.A.; Hingh, I.H.J.T. de; Wouw, Agnès J. van de; Laarhoven, Hanneke W. M. van; Lemmens, V.E.P.P.

doi:10.1016/j.ejca.2018.06.032

Cited by 34 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13,32] While histopathology is considered part of the diagnostic approach to identify the primary tumor in CUP patients, [32] only 50% of registered CUP cases in our study were histopathologically verified. This is lower than observed in other population-based studies of CUP [2,7,11,15,33] but higher than our previous study in Australian veterans (36%). [8,15] CUP is a heterogeneous diagnosis, and encompasses individuals who may have undergone exhaustive investigation but a primary site cannot be identified (i.e.…”

Section: Plos Onecontrasting

confidence: 85%

“…Cancer of unknown primary site (CUP) is the 14 th most commonly diagnosed cancer and the 6 th most common cause of cancer death in Australia. [1] It is characterized by metastatic disease with an unidentified primary site, and extremely poor survival; [2][3][4][5] in Australia, the 5-year survival rate is 13%. [6] Population-based CUP incidence rates have declined over time, [2,6,7] a trend that can most likely be attributed to advances in diagnostic investigations.…”

Section: Introductionmentioning

confidence: 99%

“…[1] It is characterized by metastatic disease with an unidentified primary site, and extremely poor survival; [2][3][4][5] in Australia, the 5-year survival rate is 13%. [6] Population-based CUP incidence rates have declined over time, [2,6,7] a trend that can most likely be attributed to advances in diagnostic investigations. While a diagnosis of CUP ideally should be limited to people with a histological confirmation of metastatic cancer, in whom thorough testing has failed to identify the site of the primary tumor, people registered with a diagnosis of CUP in population-based cancer registries are heterogeneous, with many people receiving a diagnosis based on clinical examination only.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP)

et al. 2020

View full text Add to dashboard Cite

Background Cancer of unknown primary (CUP) is a late-stage malignancy with poor prognosis, but we know little about what diagnostic tests and procedures people with CUP receive prior to diagnosis. The purpose of this study was to determine how health service utilisation prior to diagnosis for people with cancer-registry notified CUP differs from those notified with metastatic cancer of known primary. Methods We identified people with a cancer registry notification of CUP (n = 327) from the 45 and Up Study, a prospective cohort of 266,724 people �45 years in New South Wales, Australia, matched with up to three controls with a diagnosis of metastatic cancer of known primary (n = 977). Baseline questionnaire data were linked to population health data to identify all health service use, diagnostic tests, and procedures in the month of diagnosis and 3 months prior. We used conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results After adjusting for age and educational attainment, people with a cancer-registry notified CUP diagnosis were more likely to be an aged care resident (OR = 2.78, 95%CI 1.37-5.63), have an emergency department visit (OR = 1.65, 95%CI 1.23-2.21), serum tumor marker tests (OR = 1.51, 95%CI 1.12-2.04), or a cytology test without immunohistochemistry (OR = 2.01, 95%CI 1.47-2.76), and less likely to have a histopathology test without immunohistochemistry (OR = 0.43, 95%CI 0.31-0.59). Neither general practitioner, specialist, allied health practitioner or nurse consultations, hospitalisations, nor imaging procedures were associated with a CUP diagnosis.

show abstract

Section: Plos Onecontrasting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…40%) and lymph nodes (ca. 20%) 2,7 . In the Netherlands, the overall median survival for patients with a CUP diagnosis between 2010 and 2012 was 1.7 months 2 .…”

Section: Introductionmentioning

confidence: 98%

Alcohol consumption, cigarette smoking and cancer of unknown primary risk: Results from the Netherlands Cohort Study

Hermans

Brandt

Loef

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Cancer of unknown primary (CUP) is a metastasised malignancy with no identifiable primary tumour origin. Despite the frequent occurrence and bleak prognosis of CUP, research into its aetiology is scarce. Our study investigates alcohol consumption, tobacco smoking and CUP risk. We used data from the Netherlands Cohort Study, a cohort that includes 120 852 participants aged 55 to 69 years, who completed a self‐administered questionnaire on cancer risk factors at baseline. Cancer follow‐up was established through record linkage to the Netherlands Cancer Registry and Dutch Pathology Registry. After 20.3 years of follow‐up, 963 CUP cases and 4288 subcohort members were available for case‐cohort analyses. Multivariable‐adjusted hazard ratios (HRs) were calculated using proportional hazard models. In general, CUP risk increased with higher levels of alcohol intake (Ptrend = .02). The association was more pronounced in participants who drank ≥30 g of ethanol per day (HR: 1.57, 95% confidence interval [CI]: 1.20‐2.05) compared to abstainers. Current smokers were at an increased CUP risk (HR: 1.59, 95% CI: 1.29‐1.97) compared to never smokers. We observed that the more the cigarettes or the longer a participant smoked, the higher the CUP risk was (Ptrend = .003 and Ptrend = .02, respectively). Interaction on additive scale was found for participants with the highest exposure categories of alcohol consumption and cigarette smoking frequency and CUP risk. Our findings demonstrate that alcohol consumption and cigarette smoking are associated with increased CUP risk. Lifestyle recommendations for cancer prevention regarding not drinking alcohol and avoiding exposure to smoking are therefore also valid for CUP.

show abstract

“…1 It is estimated that CUP accounts for approximately 3%-5% of all newly diagnosed carcinomas 2 and there are about 4-19 cases per 100,000 persons every year, 3 although the exact incidence rate is hard to determine for various objective reasons. About 70%-80% of CUP histopathology is metastatic adenocarcinoma 2,4 and more than 60% patients present with metastasis in internal organs, 4,5 so metastatic adenocarcinoma of unknown primary site (MACUP) takes up the vast majority of the CUP. Patients with CUP usually receive empirical chemotherapy with a platinum-taxane regimen, 6 but remain poor prognosis with the median survival of approximately 6-9 months.…”

Section: Introductionmentioning

confidence: 99%

Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site

Shao

Sheng

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012

Cited by 34 publications

References 36 publications

Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP)

Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP)

Alcohol consumption, cigarette smoking and cancer of unknown primary risk: Results from the Netherlands Cohort Study

Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site

Contact Info

Product

Resources

About